Hyloris Appoints Jean-Luc Vandebroek as Chief Financial Officer
23 Settembre 2021 - 7:00AM
Hyloris Appoints Jean-Luc Vandebroek as Chief Financial Officer
- Brings >25 years of executive
financial leadership
Liège, Belgium –
23 September
2021 – Hyloris Pharmaceuticals SA (Euronext Brussels:
HYL), a specialty biopharma company committed to
addressing unmet medical needs through reinventing existing
medications, today announces that Jean-Luc Vandebroek will be
joining the Company as its Chief Financial Officer. In addition to
his new role at Hyloris, Jean-Luc will remain Non-Executive
Director of the Board of Bone Therapeutics during a transition
period to lead a managed succession. Jean-Luc will report to
Hyloris’ CEO, and previously acting interim CFO, Stijn Van
Rompay.
Jean-Luc Vandebroek is a seasoned executive who
most recently served as CFO of Bone Therapeutics, a publicly traded
biotech company based in Gosselies, Belgium. Prior to that, he was
CFO and CIO at Alcopa and Fluxys, and before that, he held various
senior financial positions at Delhaize Group. Jean-Luc is an
experienced Executive Board member and has a track record of
developing and implementing financing strategies and transactions
and has a large, global network of investors and financial
institutions. Jean-Luc holds a Master in Business Administration
from the Louvain Management School.
Jean-Luc Vandebroek,
Chief Financial Officer of
Hyloris, commented: “I
am very excited to join this unique and fast-growing company and
look forward to working with the team and start interacting with
investors and analysts over the next coming weeks. I am committed
to leveraging my expertise to support the company to realise its
ambition of becoming a global leader in patented, reformulated and
repurposed value-added medicines.”
Stijn Van Rompay,
Chief Executive Officer of
Hyloris, added: “On behalf of our staff and our Board of
Directors, I am very pleased to welcome Jean-Luc as our Chief
Financial Officer. His demonstrated track record of biotech
financing and executive leadership will be incremental as we
further expand our shareholders’ base internationally and prepare
for the next growth phase of our Company. We remain on track to
deliver on our promise to enlarge our R&D portfolio with 4 new
product candidates this year and look forward to updating the
market on our progression over the coming period.”
About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company focused on innovating,
reinventing, and optimising existing medications to address
important healthcare needs and deliver relevant improvements for
patients, healthcare professionals and payors. Hyloris has built a
broad, patented portfolio of 13 reformulated and repurposed
value-added medicines that have the potential to offer significant
advantages over available alternatives. Two products are currently
in initial phases of commercialisation with partners: Sotalol IV
for the treatment of atrial fibrillation, and Maxigesic® IV, a
non-opioid post-operative pain treatment. The Company’s development
strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway,
which is specifically designed for pharmaceuticals for which safety
and efficacy of the molecule have already been established. This
pathway can reduce the clinical burden required to bring a product
to market, and significantly shorten the development timelines and
reduce costs and risks. Hyloris is based in Liège, Belgium. For
more information, visit www.hyloris.com and follow-us on LinkedIn.
For more information, please
contact Hyloris
Pharmaceuticals: Marieke VermeerschVP
Investor Relations and Corporate CommunicationsM: +32 (0)479 490
603investorrelations@hyloris.com
Disclaimer and forward-looking
statementsHyloris means “high yield, lower risk”, which
relates to the 505(b)(2) regulatory pathway for product approval on
which the Issuer focuses, but in no way relates or applies to an
investment in the Shares.Certain statements in this press release
are “forward-looking statements.” These forward-looking statements
can be identified using forward-looking terminology, including the
words "believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. These statements relate to future events or the Company’s
future financial performance and involve known and unknown risks,
uncertainties, and other factors, many of which are beyond the
Company’s control, that may cause the actual results, levels of
activity, performance or achievements of the Company or its
industry to be materially different from those expressed or implied
by any forward-looking statements. The Company undertakes no
obligation to publicly update or revise forward-looking statements,
except as may be required by law.
- 210923 Hyloris Press Release CFO Appointment_ENG
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Apr 2023 a Apr 2024